Although still a fairly rare disease, developments in treating pulmonary arterial hypertension (PAH) have not been slow and resulted in a remarkable shift in prescribing patterns.
It has been shown that initial combination therapies in PAH can improve clinical outcomes in patients . Although treatment guidelines may recommend certain prescribing patterns for patients, data from Ipsos’ Global PAH Therapy Monitor (TM; a retrospective medical chart review with physicians reporting on the last five PAH patients seen within the last 3 months) suggest there has been a gradual shift in recent years. In fact, more newly diagnosed patients (defined as patients who have been diagnosed within the last 12 months) are receiving a combination therapy whilst there is a decline in the prescribing of monotherapies for these patients .
The objective of the study by Allie et al. was to explore treatment patterns of newly diagnosed PAH patients in the SUSA vs 3 EU...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« High 5-year survival rates for older HF patients without initial severe comorbidity Next Article
P2Y12 inhibitor monotherapy is a novel antiplatelet strategy after short duration DAPT »
Table of Contents: ACC 2019
Acute and Stable Ischaemic Heart Disease
Arrhythmias and Clinical Electrophysiology
Congenital Heart Disease
Heart Failure and Cardiomyopathies
Pulmonary Arterial Hypertension and Venous Thromboembolism
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.